Detalhe da pesquisa
1.
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
Future Oncol
; 20(10): 593-601, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37593881
2.
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
BMC Cancer
; 22(1): 1302, 2022 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36514034
3.
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Oncologist
; 26(11): e2053-e2060, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34313371
4.
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(7): 923-934, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32511981
5.
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
Future Oncol
; 16(1): 4251-4264, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31755321
6.
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Cancer
; 123(16): 3080-3087, 2017 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28440955
7.
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Gynecol Oncol
; 147(2): 402-407, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843653
8.
Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
J Oncol Pharm Pract
; 22(5): 666-78, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26320127
9.
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
Invest New Drugs
; 33(1): 138-47, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25248752
10.
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Nat Med
; 30(2): 498-506, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38182785
11.
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Eur J Cancer
; 192: 113245, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37598656
12.
Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.
Clin Pharmacol Drug Dev
; 11(10): 1165-1176, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35560823
13.
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 40(34): 3918-3928, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35947817
14.
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.
Clin Cancer Res
; 27(23): 6333-6342, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34503977
15.
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Mol Cancer Ther
; 20(11): 2098-2109, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433663
16.
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
Eur J Cancer
; 155: 236-244, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34391056
17.
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
J Clin Oncol
; 38(28): 3294-3303, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32804590
18.
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Cancer Cell
; 35(5): 738-751.e9, 2019 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31085175
19.
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
J Clin Oncol
; 35(10): 1112-1118, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28029313
20.
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Neoplasia
; 18(12): 775-784, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27889646